Sacred Reciprocity, Biocultural Conservation, and Honouring our Indigenous Ancestors with Chacruna’s Joseph Mays
Similar Posts
MindCure CEO Kelsey Ramsden – The Psychedelic Space Is Unlike Any Other Drug Development Sector
In this interview with Kelsey Ramsden, CEO on MindCure Health…
5 MeO-DMT: Throwing the Grenade into the Lake of Your Subconscious Mind with Tandava Retreats
In this episode of the Psychedelic Spotlight podcast, Swati sits…
Field Trip Health Treating Depression With Ketamine-Assisted Therapy All Across North America (FTRP)
Ronan Levy, founder of Field Trip Health (NASDAQ: FTRP, TSX:…
Spider-Man’s Secret War: How the Web Crawler and Stan Lee Promoted the War on Drugs
Spider-Man’s Secret War: How the Web Crawler and Stan Lee…
BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)
Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG MindMed MDMA Trial, Atai’s to Compete with Tesla’s Neuralink (+Updates on CMPS, MYCO and ENBI)” might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” That is if you are interested in the general developments in the psychedelic industry for this week.
In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.
1. We’ll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ]
2. Atai Life Sciences’ Computer Brain Interface & their clinical trial to treat Schizophrenia
3. Compass Pathways (CMPS) has amazing new price targets
4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials
5. Entheon’s (ENBI / ENTBF) new Genetic Test Kit Updates
…
Timestamps:
0:00 – Intro
1:47 – MindMed’s (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing
6:08 – Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder
8:00 – Atai’s Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia
9:07 – Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update
10:32 – Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 )
13:02 – Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen’s Psychedelics’ Genetic KIT
So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!
I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifa
…
https://benzinga.grsm.io/thepsychedel
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDStock #CMPS Stock
Does Jon Stewart Microdose Magic Mushrooms? | Plus Pirate Eye
Does Jon Stewart Microdosing Magic Mushrooms?
Have you ever wanted to try microdosing magic mushrooms before, because Jon Stewart wants to! On a recent podcast episode of The Problem with Jon Stewart, the political comedian opened his show by saying “I’ve been microdosing the whole week!”, before clarifying that he just WANTS to try psychedelic microdosing.
The satirist, sometimes known as America’s Conscience, is one of the most influential voices in media over the last 3 decades. His short and funny forrow into the psychedelics debate should help further propel the issue into the mainstream.
Can microdosing help depression? Can Microdosing help mental health? Jon Stewart thinks so, though this claim needs to be verified by the medical establishment.
Microdosing has become a popular trend for professionals in the last few decades, so it is not surprising that Jon Stewart knows about it. He is a man with his finger on America’s pulse.
Link to podcast: https://open.spotify.com/episode/3OZV5DLbn33bNSUluLS7oX?si=qVoGF4cCS76x_MrM9h_slw
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
#jonstweart #thejonsteartproblem #psychedelics